ReviewPain2020
Peripheral pain mechanisms in osteoarthritis.
Review in Pain, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 127 citations in OpenAlex.
- Responders vs. non-responders to mesenchymal stromal cells in knee osteoarthritis: Mechanistic correlates of donor cell and patient features.Stem cell reports · 2026Trial
- 3D Light sheet microscopy reveals aging osteoarthritis-associated joint-innervated nerve remodeling in mouse knee joints.Osteoarthritis and cartilage · 2026Article
- Heterogeneity of treatment effects in transcranial direct current stimulation for knee osteoarthritis pain and symptoms.Pain reports · 2026Article
- Osteoarthritis as a systemic disorder: multi-organ crosstalk in pathogenesis and therapeutic targeting.Frontiers in immunology · 2026Review
- Pain sensitization as a potentially modifiable factor in people with knee osteoarthritis: insights from behavioral graded activity.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Neuroimmune crosstalk in osteoarthritis pain: from synovial inflammation to pain sensitization.Frontiers in immunology · 2026Review
- Translating Osteoarthritis Genetic Risk Into Biomarkers: Opportunities, Pitfalls, and Implementation Considerations.Human mutation · 2026Review
- Neuropeptide Y signaling in osteoarthritis pain: neuroimmune mechanisms, joint remodeling, and translational opportunities.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Complement factor D (adipsin) mediates pressure-pain hypersensitivity post destabilization of medial meniscus injury.Arthritis research & therapy · 2025Article
- Fast-conducting mechanonociceptors uniquely engage reflexive and affective pain circuitry to drive protective responses.bioRxiv : the preprint server for biology · 2025Article
- Understanding pain heterogeneity in osteoarthritis patients: a narrative review.Frontiers of medicine · 2025Review
- Knee Osteoarthritis: Current Insights Into Pathophysiology and Non-surgical Management Options.Cureus · 2025Review
- Knee osteoarthritis rehabilitation: an integrated framework of exercise, nutrition, biomechanics, and physical therapist guidance-a narrative review.European journal of medical research · 2025Review
- Unraveling Osteoarthritis: Mechanistic Insights and Emerging Therapies Targeting Pain and Inflammation.Biomolecules · 2025Review
- Deciphering cartilage neuro-immune interactions and innervation profile through 3D engineered osteoarthritic micropathophysiological system.Materials today. Bio · 2025Article
- Neurovascularization inhibiting dual responsive hydrogel for alleviating the progression of osteoarthritis.Nature communications · 2025Article
- Effect of regional crosstalk between sympathetic nerves and sensory nerves on temporomandibular joint osteoarthritic pain.International journal of oral science · 2025Article
- Role of transient receptor potential (TRP) channels in osteoarthritis: a comprehensive review.Frontiers in pharmacology · 2025Review
- Dual Roles of Prostaglandin E2 (PGE2) in Bone Remodeling and Pain Management: Bridging the Gap in Osteoarthritis Research.Mediators of inflammation · 2025Review
- A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis.Frontiers in veterinary science · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
There is a well-established historical observation that structural joint damage by plain X-ray correlates poorly with symptomatic disease in osteoarthritis (OA). This is often attributed to the inability to visualise soft-tissue pathology within the joint and the recognition of heterogeneous patient factors that drive central pain sensitisation. A major issue is the relative paucity of mechanistic studies in which molecular pathogenesis of pain is interrogated in relation to tissue pathology. Nonetheless, in recent years, three broad approaches have been deployed to attempt to address this: correlative clinical studies of peripheral and central pain outcomes using magnetic resonance imaging, where soft-tissue processes can be visualised; molecular studies on tissue from patients with OA; and careful molecular interrogation of preclinical models of OA across the disease time course. Studies have taken advantage of established clinical molecular targets such as nerve growth factor. Not only is the regulation of nerve growth factor within the joint being used to explore the relationship between tissue pathology and the origins of pain in OA, but it also provides a core model on which other molecules present within the joint can modulate the pain response. In this narrative review, how molecular and pathological tissue change relates to joint pain in OA will be discussed. Finally, a model for how tissue damage may lead to pain over the disease course will be proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.